Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer

Completed

Conditions studied: Malignant Neoplasm

In brief

This clinical trial studies a novel single wave assessment in measuring cardiac dysfunction and metabolic syndrome in patients with cancer. The novel single wave assessment is a hand held device that can report left ventricular ejection fraction, which measures how well the heart is pumping blood (by giving a percentage) and measures how stiff the arteries are in the heart (pulse wave velocity). A novel single wave assessment may help identify patients at increased risk for type II diabetes and metabolic syndrome (disease where patients have increased blood pressure and high blood sugar level and excess body fat around the waist and abnormal cholesterol levels).

Key facts

Study ID

NCT04014231

Run by

City of Hope Medical Center

People needed

159

Starts

2017-07-21

Expected to finish

2026-04-20

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients undergoing 2D echocardiogram at City of Hope (COH)
• Patients with a current or past diagnosis of cancer
• Ability to sign a written informed consent

You may not qualify if…

• Inability to provide informed consent
• Patients who have known "carotid sinus hypersensitivity"
• Patients who do not consent to blood draw
• Patients who have not fasted for the instructed time prior to blood draw

Where it is running

• City of Hope Medical Center — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.